Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL.

被引：0
|
作者：
Wierda, WG [1 ]
OBrien, S [1 ]
Ferrajoli, A [1 ]
Faderl, S [1 ]
Koller, C [1 ]
Giles, F [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Ravandi, F [1 ]
Garcia-Manero, G [1 ]
Andreeff, M [1 ]
Lerner, S [1 ]
Kantarjian, H [1 ]
Keating, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
719
引用
收藏
页码：213A / 213A
页数：1
相关论文
共 48 条
  • [21] Final results of lower dose fludarabine (F) and cyclophosphamide (C), and high dose rituximab (R), (FCR-Lite) for patients with untreated chronic lymphocytic leukemia (CLL)
    Tarhini, Ahmad A.
    Land, S.
    Pietragallo, L.
    Laman, A.
    Sulecki, M.
    Marks, S.
    Meisner, D.
    Schaefer, P. M.
    Foon, Kenneth A.
    BLOOD, 2007, 110 (11) : 606A - 607A
  • [22] A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs).
    Faderl, S.
    Wierda, W.
    O'Brien, S.
    Ferrajoli, A.
    Detry, M.
    Ravandi, F.
    Kantarjian, H. M.
    O'Neal, B.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 362S - 362S
  • [23] The combination of oxaliplatin, fludarabine-(FLU), cytarabine (Ara-c), and rituximab (R) (OFAR) in patients with Richter's transformation and FLU-refractory CLL.
    Wierda, W.
    Tsimberidou, A.
    O'Brien, S.
    Ferrajoli, A.
    Faderl, S.
    Ravandi, F.
    Cortes, J.
    Kantarjian, H.
    Plunkett, W.
    Keating, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 362S - 362S
  • [24] Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)
    Hallek, Michael
    Fingerle-Rowson, Guenter
    Fink, Anna-Maria
    Busch, Raymonde
    Mayer, Jiri
    Hensel, Manfred
    Hopfinger, Georg
    Hess, Georg
    von Gruenhagen, Ulrich
    Bergmann, Manuela A.
    Catalano, John
    Zinzani, Pier Luigi
    Cappio, Federico Caligaris
    Seymour, John Francis
    Berrebi, Alain
    Jaeger, Ulrich
    Cazin, Bruno
    Trneny, Marek
    Westermann, Anne
    Wendtner, Clemens-Martin
    Eichhorst, Barbara F.
    Staib, Peter
    Boettcher, Sebastian
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Mendila, Myriam
    Kneba, Michael
    Doehner, Hartmut
    Fischer, Kirsten
    BLOOD, 2008, 112 (11) : 125 - 125
  • [25] Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients
    Musto, Pellegrino
    Fraticelli, Vincenzo Ludovico
    Mansueto, Giovanna
    D'Arena, Giovanni
    Petrilli, Maria Pia
    Gasbarrino, Cristiana
    Farina, Giuliana
    Guariglia, Roberto
    Martorelli, Maria Carmen
    Villani, Oreste
    Pietrantuono, Giuseppe
    Catalano, Lucio
    Madonna, Emanuela
    Nozza, Andrea
    Andriani, Alessandro
    Montefusco, Vittorio
    Mussetti, Alberto
    Lipari, Maria Grazia
    Ballanti, Stelvio
    Bongarzoni, Velia
    Tamiazzo, Stefania
    Patriarca, Francesca
    Vincelli, Donatella
    Falcone, Antonietta
    Derudas, Daniele
    Califano, Catello
    Zambello, Renato
    Mele, Giuseppe
    Fragasso, Alberto
    Baldini, Luca
    Palumbo, Antonio
    Storti, Sergio
    BLOOD, 2012, 120 (21)
  • [26] FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone
    Dornan, David
    Spleiss, Olivia
    Yeh, Ru-Fang T.
    Duchateau-Nguyen, Guillemette
    Robak, Tadeusz
    Moiseev, Sergey I.
    Dmoszynska, Anna
    Solal-Celigny, Philippe
    Warzocha, Krzysztof
    Loscertales, Javier
    Catalano, John
    Afanasiev, Boris V.
    Larratt, Loree
    Rossiev, Viktor A.
    Bence-Bruckler, Isabelle
    Geisler, Christian H.
    Montillo, Marco
    Wenger, Michael K.
    Weisser, Martin
    BLOOD, 2009, 114 (22) : 923 - 923
  • [27] Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).
    Parikh, S. A.
    Wierda, W. G.
    Badoux, X.
    O'Brien, S. M.
    Ferrajoli, A.
    Faderl, S.
    Burger, J. A.
    Lerner, S.
    Kantarjian, H.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)
    Douglas, P.
    Lee, R.
    Worthington, K.
    Mistry, B.
    VALUE IN HEALTH, 2011, 14 (03) : A160 - A160
  • [29] IgVH mutational status does not affect complete remission rate but is associated with reduced remission duration in CLL patients treated with fludarabine, cyclophosphamide and rituximab (FCR)-based therapy
    Lin, Katherine I.
    Tam, Constantine S.
    Abruzzo, Lynne V.
    Wierda, William
    Barron, Lynn
    O'Brien, Susan
    Kipps, Thomas
    Rassenti, Laura
    Lerner, Susan
    Kantarjian, Hagop
    Keating, Michael J.
    BLOOD, 2007, 110 (11) : 232A - 232A
  • [30] Combined therapy of rituximab, fludarabine and cyclophosphamide (R-FC) as a first-line treatment is safe and efficacious for younger patients with B-cell chronic lymphocytic leukemia (B-CLL).
    Ranze, OP
    Arland, M
    Hoffkes, HG
    BLOOD, 2003, 102 (11) : 355B - 356B
12345